LA JOLLA, CA, April 30, 2024 – Enlaza Therapeutics, the first covalent biologic platform company, today announced a $100 million Series A financing. The financing will be used to further...
Bioinformatics on the Brink (The Scientist)
News | 12. 20. 2004
Companies struggle to diversify after disappointing software sales sink the sector.
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.